What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality
Claesson-Welsh (2019) What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality EMBO Mol Med (IF: 11.1) 11(8) e10892Abstract
In this issue of EMBO Molecular Medicine, Uribesalgo and coworkers show that high Apelin expression correlates with poor survival in advanced breast (MMTV-NeuT) and lung (KRASG12D ) murine tumor models as well as in breast and lung cancer in humans. Combining Apelin inhibition (genetically or using an inactive Apelin agonist) with anti-angiogenic therapy using different small molecular weight kinase inhibitors (sunitinib, axitinib) led to marked delay in breast cancer growth in mice. The vasculature in Apelin-targeted cancer showed normalized features including improved perfusion and reduced leakage. These important data provide a strong incentive to target Apelin in human cancer treatment.© 2019 The Author. Published under the terms of the CC BY 4.0 license.
Links
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685083http://www.ncbi.nlm.nih.gov/pubmed/31318171
http://dx.doi.org/10.15252/emmm.201910892